Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY4268989 (MORF-057) plus mirikizumab in adults with moderately to severely active ulcerative colitis
CTR20260470Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LY4268989 and mirikizumab in autoimmune colitis (2 arms), sponsored by Eli Lilly and Company. Started Apr 2026; status: active.
02
Drugs
LY4268989mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20260470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260470.